Literature DB >> 22258825

4G/5G polymorphism modulates PAI-1 circulating levels in obese women.

Karla S Fernandes1, Valéria C Sandrim.   

Abstract

The increase in plasminogen activator inhibitor type 1 (PAI-1) has been described as a risk factor to thrombosis-related diseases. In addition, it has been demonstrated that the variant 4G of polymorphism 4G/5G located in promoter region of PAI-1 gene is associated with higher PAI-1 levels. We investigate the role of this polymorphism on circulating PAI-1 concentration in a population of 57 obese women (23%, 4G/4G; 49%, 4G/5G and 28%, 5G/5G genotypes). Our results demonstrate a genotype-specific modulation on PAI-1 levels in obese women, thus 5G/5G genotype presented significantly lower levels of plasma PAI-1 when compared to 4G/4G group (46 ± 19 ng/mL vs. 63 ± 13 ng/mL, respectively). Our findings indicate that obese carriers of 4G/4G genotype may have increased risk to develop thrombotic diseases.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22258825     DOI： 10.1007/s11010-012-1230-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN： 0300-8177            Impact factor:   3.396


  15 in total

1.  Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects.

Authors:  P Vague; I Juhan-Vague; M F Aillaud; C Badier; R Viard; M C Alessi; D Collen
Journal:  Metabolism       Date:  1986-03       Impact factor: 8.694

2.  Plasminogen activator inhibitor 1 gene polymorphism and gestational diabetes mellitus.

Authors:  Heinz Leipold; Martin Knoefler; Christian Gruber; Katharina Klein; Peter Haslinger; Christof Worda
Journal:  Obstet Gynecol       Date:  2006-03       Impact factor: 7.661

3.  Rapid, homogeneous genotyping of the 4G/5G polymorphism in the promoter region of the PAII gene by fluorescence resonance energy transfer and probe melting curves.

Authors:  M Nauck; H Wieland; W März
Journal:  Clin Chem       Date:  1999-08       Impact factor: 8.327

Review 4.  Obesity and thrombosis.

Authors:  K A L Darvall; R C Sam; S H Silverman; A W Bradbury; D J Adam
Journal:  Eur J Vasc Endovasc Surg       Date:  2006-12-20       Impact factor: 7.069

5.  Angiotensinogen, angiotensine converting enzyme and plasminogen activator inhibitor-1 gene polymorphism in chronic allograft dysfunction.

Authors:  Negar Azarpira; M Bagheri; Gh A Raisjalali; M H Aghdaie; S Behzadi; H Salahi; M Rahsaz; M Darai; M J Ashraf; B Geramizadeh
Journal:  Mol Biol Rep       Date:  2008-05-03       Impact factor: 2.316

6.  Overweight, obesity, and the risk of recurrent venous thromboembolism.

Authors:  Sabine Eichinger; Gregor Hron; Christine Bialonczyk; Mirko Hirschl; Erich Minar; Oswald Wagner; Georg Heinze; Paul A Kyrle
Journal:  Arch Intern Med       Date:  2008-08-11

7.  Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes.

Authors:  M W Mansfield; M H Stickland; P J Grant
Journal:  Thromb Haemost       Date:  1995-10       Impact factor: 5.249

8.  Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction.

Authors:  Loukianos S Rallidis; Argyri Gialeraki; Efrosyni Merkouri; George Liakos; Nikolaos Dagres; Dimitrios Sionis; Anthi Travlou; John Lekakis; Dimitrios T Kremastinos
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

9.  Plasminogen activator inhibitor-1 polymorphism is associated with progressive renal dysfunction after acute rejection in renal transplant recipients.

Authors:  Kai Ming Chow; Cheuk Chun Szeto; Carol Yi-Ki Szeto; Peter Poon; Fernand Mac-Moune Lai; Philip Kam-Tao Li
Journal:  Transplantation       Date:  2002-12-27       Impact factor: 4.939

10.  Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients.

Authors:  J B McGill; D J Schneider; C L Arfken; C L Lucore; B E Sobel
Journal:  Diabetes       Date:  1994-01       Impact factor: 9.461
View more
  3 in total

1.  The Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction.

Authors:  Tajinder Kumar Parpugga; Vacis Tatarunas; Vilius Skipskis; Nora Kupstyte; Diana Zaliaduonyte-Peksiene; Vaiva Lesauskaite
Journal:  Dis Markers       Date:  2015-07-26       Impact factor: 3.434

2.  Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study.

Authors:  Manal S Fawzy; Eman A Toraih; Nagwa M Aly; Abeer Fakhr-Eldeen; Dahlia I Badran; Mohammad H Hussein
Journal:  BMC Cardiovasc Disord       Date:  2017-01-13       Impact factor: 2.298

3.  Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women.

Authors:  Merih Ozgen; Didem Turgut Cosan; Fulya Doganer; Ahu Soyocak; Onur Armagan; Hasan Veysi Gunes; Irfan Degirmenci; Gulsah Ogutler Ozkara; Fezan Sahin Mutlu
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.